+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2023

  • PDF Icon


  • 312 Pages
  • December 2022
  • Region: Global
  • BioInformant
  • ID: 5313562

Exosome technologies have been developing rapidly in recent years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine, and regenerative medicine. In particular, cancer-derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection. 

Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers. Exosomes are secreted by a wide range of cells, since virtually all living cells utilize exosome-mediated communication. Exosomes carry cell-specific cargos of proteins, lipids, and nucleic acids that are selectively taken up by recipient cells.

The cargo contained within exosomes can offer prognostic information for range of diseases - including cardiovascular, renal, neurodegenerative, and metabolic diseases - as well as cancer.  Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including using exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.

Importantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears, and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient's response to a specific course of treatment.

Exosomes are also being explored for their use as cell-free therapeutics. For example, suppose a patient has a disease caused by a missing or defective protein or microRNA. In that case, the patient’s exosomes can be isolated, modified with the appropriate siRNA or protein, and then injected back into the patient for treatment. Many approaches are being researched for creating drug-loaded exosomes. Furthermore, exosomes themselves can exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.

For these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits.

When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and China comes in second place. When the term "exosome" is searched in the scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author. When the term "extracellular vesicles" is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead. Headquartered in Switzerland, the company has published more than 100 papers on exosomes and extracellular vesicles in combination with Professor Giovanni Camussi.

To date, three pharma companies (Takeda, Jazz Pharmaceuticals, and Roche Pharmaceutical Company) have signed partnership deals with exosome companies offering payment terms structured to deliver at or around $1 billion dollars. Within the past few years, there has been at least 7 partnership deals within the exosome industry, 8 large venture capital events, and 2 landmark acquisitions.

The exosome industry has also achieved two landmark approvals of FDA-approved diagnostic tests: Bio-Techne's ExoDx Prostate IntelliScore Test for prostate cancer and Guardant's 360 CDx test for non-small cell lung cancer.

Exosome Market Forces

The publisher has released this global market report to characterize the rapidly expanding exosome market that explores growing demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies. The report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials.

It highlights information about exosome industry partnerships, merger and acquisition (M&A) activity, and financing events. It features company profiles for 118 global competitors from across the exosome marketplace. Importantly, it presents market size determinations by market segment with forecasts through 2030.

Today the exosome industry is witnessing:

  • A surging number of scientific papers investigating exosomes and their applications
  • Rising numbers of clinicals trials investigating exosome therapeutics and diagnostics
  • Swelling appetite among investors for exosome technologies
  • An increasingly competitive IP environment
  • A diverse range of co-development partnerships
  • Proliferating numbers of exosome competitors in all major life science markets worldwide

Table of Contents

1.1  Statement of the Report
1.2  Target Demographic
1.3  Report Sources
1.4  Purpose of the Report
1.5  Executive Summary
1.6  Introduction 

2.1  Structure of an Exosome   
2.1.1 Molecular Contents of Exosomes Proteins in Exosomes Lipid Contents of Exosomes Nucleic Acids in Exosomes   
2.1.2 Components of Membrane and Lumen of Exosomes   
2.2  Classification of Exosomes   
2.2.1 Natural Exosomes Isolation of Natural Exosomes   
2.2.2 Modified Exosomes Types of Therapeutic Cargo used in Exosome Modifications   
2.2.3 Synthetic Exosomes   
2.3  Biomedical Applications of Engineered Exosomes   
2.4  Functions of Exosomes   
2.4.1 Pivotal Role of Exosomes   
2.4.2 Adaptability to Engineering   
2.5  Differences between Exosome Therapy and Cell Therapy   
2.6  Sources of Exosomes for Research   
2.7  Leveraging Exosomes as Biomarkers   
2.8  The Shift from Cell Therapy to Exosome Therapy   

3.1  Interior Modification   
3.1.1 Pre-Isolation Interior Modification Methods Incubation Gene Editing   
3.1.2 Post-Isolation Interior Modification Methods   
3.2  Surface Modifications   
3.2.1 Surface Modification through Parent Cells   
3.2.2 Direct Surface Modification   
3.2.3 Loaded and Displayed Molecules in Direct Exosome Engineering   
3.3  Comparison of Modification Methods   
3.4  Clinical Applications of Designer Exosomes   
3.4.1 Targeted Designer Exosomes   
3.4.2 Anti-Cancer Designer Exosomes   
3.4.3 Regenerative Designer Exosomes   
3.5  Companies Developing Engineered Exosome-Based Therapeutics   

4.1  Cardiovascular Diseases   
4.2  Kidney Diseases   
4.3  Liver Diseases   
4.4  Wound Healing   
4.5  MSC Exosome-Based Clinical Trials for Regenerative Medicines   

5.1  Research to Inhibit Disease-Derived Exosomes   
5.1.1 Research to use Exosomes as Therapeutic Platforms   
5.1.2 Research to use Exosomes as Carriers of Genes in Gene Therapy   
5.1.3 Research to use Exosomes as Drug Delivery Vehicles   
5.1.4 Research to Develop Technologies for Exosome Isolation   
5.2  Common Isolation Methods in Exosome Research   
5.3  Quality Control (QC) of Exosomes in Exosome Research   
5.4  Bioimaging Modalities used in Exosome Research   
5.5  Labeling Methods used in Exosome Research   
5.5.1 Fluorescent Dyes used in Labeling Exosomes   
5.5.2 Common Methods to Remove Unlabelled Probes   
5.6  Determination of Exosome Dose in Exosome Studies   
5.7  Routes of Exosome Administration   
5.8  Characterization of Exosomes in Research   

6.1  Exosome Capture/Quantification Kits   
6.1.1 Exosome-associated RNA Isolation Kits   
6.2  Exosome Standards   
6.3  Immunoplates for Capturing Exosomes   
6.4  Immunobeads for Exosome Isolation   
6.5  Exosome Marker Antibodies   

7.1  Trends in Global Publications   
7.1.1 Scientific Publications on Exosome DNA as Diagnostics   
7.1.2 Scientific Publications on Exosome RNA as Diagnostics   
7.1.3 Scientific Publications on Exosome Proteins as Diagnostics   
7.1.4 Scientific Publications on Exosomes Derived from Stem Cells   
7.1.5 Scientific Publications on Exosome-based Diagnostics   
7.1.6 Scientific Publications on Exosome-based Therapeutics   
7.1.7 Scientific Publications on Exosomes for Cancer Diagnosis   
7.1.8 Scientific Publications on Exosomes for Pregnancy Disorders Diagnosis   
7.2  Future in Exosome Research Publications 

8.1  A Brief Overview of Current Exosome Patent Landscape   
8.1.1 Patents/Patent Applications Relevant to Exosome-Sources   
8.1.2 Patents/Applications Related to Exosomes-Isolation/Preparation   
8.1.3 Patents/Applications Related to Type of Cargo   
8.1.4 Patents/Applications Related to Cargo Loading Methods   
8.1.5 Patents/Applications Related to Therapy Area   
8.2  Leading Assignees of Exosome Patents   
8.2.1 Types of Patented Isolation/Preparation Technologies by Assignees   
8.2.2 Types of Cargos Employed by Assignees   
8.2.3 Cargo Loading Methods by Assignees   
8.2.4  Therapy Areas by Assignees   
8.3  Exosome Patent/Patent Applications by Geography   
8.4  Legal Status of Exosome Patent/Patent Applications   
8.5  Assignee Categories   

9.1  Sources of Exosomes used in Clinical Trials   
9.2  Studies using Anti-Tumor Antigens   
9.3  Studies using Cytotoxic Drugs against Cancer   
9.4  Recruitment Status of Ongoing Exosome-based Clinical Trials   
9.5  Study Designs   
9.6  Study Phases   
9.7  Funding Types   
9.8  Exosome Clinical Trials by Geography   
9.9  Clinical Trials Involving MSC-Derived Exosomes   
9.10  Examples of Clinical Trials involving Drug-Loaded Exosomes   

10.1  Production of Exosomes from Cell Cultures   
10.2  Production Formats   
10.2.1 Large Scale Production  Upstream Cell Line Production  Downstream Exosome Purification Methods   
10.3  Companies Offering Exosome-Related Services   

11.1  Differential Ultracentrifugation   
11.1.1 Gradient Density Ultracentrifugation   
11.2  Ultrafiltration & Sequential Ultrafiltration   
11.3  Size-exclusion Chromatography   
11.4  Polymer Precipitation   
11.5  Immunoaffinity Capture   
11.6  Microfluidics-Based Techniques   
11.6.1 Active and Passive Methods of Microfluidics-based Platforms   
11.7  Commercially Available Exosome Isolation Kits   
11.7.1 Comparison of Currently used Exosome Isolation Techniques   
11.7.2 Quality of Exosomes Isolated by Different Methods   
11.8  Summary of Different Exosome Isolation Methods   
11.9  Characterization of Exosomes   
11.9.1 Size and Shape   
11.9.2 Molecular Profiling   
11.9.3 Proteomics and Lipidomics   
11.9.4 Genomics   
11.10  Microscopy and Nanoscopy for Exosome Imaging   
11.11  Direct Post-Isolation Labeling for Imaging   
11.12  Approaches for Exosome Analysis for Gene and Protein Biomarkers   
11.13  Emerging Optical Technologies for Exosome Analysis   
11.14  Emerging Electrochemical and Electromechanical Approaches   

12.1.1 Exosomal Proteins as Diagnostic Biomarkers   
11.1.2 Exosomal Nucleic Acids as Biomarkers   
12.1.3 Non-Coding RNAs in Exosomes as Biomarkers in Cancers  Exosomes from other Biofluids as Biomarkers for Cancer   
12.2  Exosome Biomarkers in Pregnancy Disorders   
12.3  Exosome Biomarkers and Early Diagnosis of Immunologic Rejection   
12.4  Number of PubMed Articles on Exosome-Based Diagnosis   
12.5  Clinical Trials involving Exosome-based Diagnostics   

13.1  Advantages of Exosomes as Therapeutics   
13.2  Therapeutic Exosome Platforms   
13.2.1 Naïve Exosome Therapeutics   
13.2.2 Engineered Exosome Therapeutics Passive Cargo Loading Active Cargo Loading   
13.3  Drugs Encapsulated in Exosomes   
13.4  Preclinical Studies involving Loaded Exosome Therapeutics   
13.5  Clinical Trials involving Exosome Therapeutics   

14.1  Exosome-Based Immunotherapy in Animal Models   
14.2  Ongoing Clinical Trials Involving Exosomes in Developing Vaccines   

15.1  The Shift from Cell Therapy to Exosome Therapy   
15.2  Clinical Applications of Exosomes   
15.2.1 Diagnostic Applications   
5.2.2 Approved Exosome Diagnostics ExoDx Prostate IntelliScore (EPI) Test Guardant360 CDx   
15.3  Clinical Trials Focusing on Exosome-Based Diagnostics   
15.4  Therapeutic Applications of Exosomes   
15.4.1 Promising Exosome-Based Therapeutic Candidates AB 126  AGLE-102  AVA-201  AVA-202  AZ001  CAP-2003  exoIL-12  ExoPr0  exoSTING  Plexaris  UNEX-42  Unexisome   
15.5  Addreseable Diseases by Exosome Therapeutic Candidates   
15.6  Exosome-Based Vaccine Development   
15.7  Current Status of Exosome-Based Clinical Trials   
15.8  NIH Funding for Exosome Research   
15.9  Deals and Fund Raising in Exosome Space   
15.9.1 Partnership Deals within Exosome Space  Exopharm and Astellas  Univercells Technologies and RoosterBio  AgeX Therapeutics and UCI  VivaZome and La Trobe University  Evotec SE and Curexsys GmbH  Bio-Techne and QIAGEN  InnoCan Pharma and Recipharms  Sarepta Therapeutics and Codiak Biosciences  Navigo Proteins and MDimune  Evox Therapeutics and Takeda  Jazz Pharmaceuticals and Codiak Biosciences  PureTech Health and Roche  Exosome Diagnostics and Intezyne  Evox Therapeutics and Boehringer Ingelheim   
15.9.2 Acquisition Deals  Lonza’s Acquisition of Exosomics  Lonza and Codiak Biosciences  Bio-Techne and Exosome Diagnostics  Lonza and HansaBioMed   
15.9.3 Licensing Deals  Evox Therapeutics and Eli Lilly  VivaZome Therapeutics and University of Adelaide  CEVEC and Evox Therapeutics  Orgenesis and Excella Bio   
15.9.4 Fund Raising in Exosome Space  Series C Financing Round by Evox Therapeutics  Series B Financing Round for ILIAS Biologics Initial Public Offering (IPO) by Codiak Biosciences Series C Funding for ExoCoBio Common Stock Financing by ArunA Bio Early-Stage Award for Evox Therapeutics Series A Funding for ExoCoBio NIH Grant for Capricor   
15.10  Current Industry Leaders in Exosome Sector   
15.10.1 ArunA Biomedical   
15.10.2 Capricor Therapeutics   
15.10.3 Codiak Biosciences   
15.10.4 Evox Therapeutics   
15.10.5 Exosome Diagnostics, Inc (Bio-Techne)   
15.10.6 Exocyte Therapeutics   
15.10.7 Kimera Labs   
15.10.8 NanoSomiX   
15.11  The Four Categories of Exosome Companies   
15.12  Current Exosome Technologies by Commercial Companies   
15.12.1 Brief Descriptions of Major Exosome Technologies and Companies  AGLE-102 from Aegle Therapeutics  CDC Exosomes from Capricor Therapeutics  engEX Platform from Codiak Biosciences  DeliverEX from Evox Therapeutics  Exo-101 from Exogenus Therapeutics  Hybridozome from Anjarium Biosciences  Neuronal Exosomes from Aruna Bio  ExoPro from ReNeuron  Plexaris from Exopharm Pty., Ltd.  ExoSCRT from ExoCoBio   

16.1  Market for Exosome Therapeutics   
16.2  The Market for Exosome Diagnostics   
16.3  Market for Exosome Research Products   
16.3.1 Market Shares for Exosome Isolation Tools   
16.3.2 Percent Utilization of Research Tools used on Captured Exosomes   

17.1  101 Bio   
17.1.1 Exosome Services   
17.2  Abbexa, Ltd.   
17.3  Abnova   
17.4  Adipomics, Inc.   
17.5  Aegle Therapeutics   
17.5.1 Extracellular Vesicle Therapy   
17.6  AgeX Therapeutics   
17.6.1 PureStem Technology   
17.6.2 Induced Tissue Regeneration   
17.6.3 UniverCyte   
17.6.4 HyStem Delivery Technology   
17.7  Aethlon Medical, Inc.   
17.7.1 Homopurifier   
17.8  Ambiotech   
17.9  AMS Biotechnology, Ltd. (AMSBIO)   
17.9.1 Products   
17.10  Anjarium Biosciences   
17.10.1 Anjarium’s Hybridosome Platform   
17.11  Antibodies-Online GmbH   
17.12  Aposcience AG   
17.12.1 Wound Healing   
17.12.2 Myocardial Infarction   
17.13  Aruna Bio   
17.13.1 AB126   
17.14  Avalon GloboCare Corp.   
17.14.1 Avalon’s Core Platforms   
17.15  Aviva Systems Biology   
17.16  Azymus Therapeutics   
17.16.1 AZ Platform   
17.17  Beckman Coulter Life Sciences   
17.17.1 Optima XPN   
17.17.2 Vi-CELL BLU - Cell Viability Analyzer   
17.17.3 SW 32 Swinging Bucket Rotor   
17.17.4 CytoFLEX - Flow Cytometer   
17.18  BioCat GmbH   
17.18.1 Exosome Purification Kits   
17.19  BioFluidica   
17.20  Biological Dynamics, Inc.   
17.20.1 Verita Isolation Platform   
17.21  Biorbyt, Ltd.   
17.22  BioRegenerative Sciences, Inc.   
17.22.1 SRM Technology   
17.23  Bio-Techne   
17.23.1 Products   
17.24  BioVision, Inc.   
17.25  BrainStorm Cell Therapeutics   
17.25.1 Exosomes for COVID-19   
17.26  BreStem Therapeutics, Inc.   
17.27  Capricor Therapeutics   
17.27.1 Exosome Program   
17.28  Carmine Therapeutics   
17.29  CD Bioparticles   
17.29.1 Exosome Services   
17.30  Cellarcus Biosciences, Inc.   
17.30.1 vFC Vesicle Analysis Assays   
17.30.2 vTag Antibodies   
17.30.3 Vesicles and Vesicle Standards   
17.30.4 Vesicle Analysis Services   
17.30.5 Measuring EV Size and Concentration   
17.30.6 Quantifying Vesicle Cargo   
17.30.7 Custom Analysis Services   
17.31  Cell Care Therapeutics   
17.31.1 CCT-101   
17.32  Cell Factory BVBA/Esperite NV   
17.32.1 Exosome Projects   
17.33  Cell Guidance Systems, Ltd.   
17.33.1 Exosomes from Cell Guidance   
17.33.2 Exo-Spin Exosome Purification   
17.33.3 Exosome Characterization   
17.33.4 ExoLISA Technology: Exosome Detection   
17.33.5 NTA Size Profiling Service   
17.34  Ciola   
17.34.1 Exosome Customization Technology   
17.35  CK-Exogene   
17.36  Clara Biotech   
17.36.1 ExoRelease   
17.37  Codiak Biosciences   
17.37.1 engEx Platform   
17.37.2 Pipeline Products  exoSTING  exolL-12 exoASO-STAT6   
17.38  Coya Therapeutics, Inc.   
17.39  Craif, Inc.   
17.39.1 Nanowire Device   
17.40  Creative Bioarray   
17.41  CreativeBiostructure   
17.42  Creative Biolabs   
17.42.1 Products   
17.42.2 Services   
17.43  Creative Medical Technology Holdings   
17.43.1 AmnioStem Stroke Therapy   
17.44  Creative Proteomics   
17.44.1 Exosome Proteomics Services   
17.45  Curexsys GmbH   
17.45.1 Technology   
17.46.1 Exosome Isolation Kits   
17.47  Diadem Biotherapeutics   
17.47.1 Technology   
17.48  Direct Bio   
17.48.1 ExoFlo   
17.48.2 AmniWrap   
17.49  DLdevelop   
17.50  Entelexo Biotherapeutics   
17.51  EverZom   
17.51.1 Services   
17.52  Evomic Science LLC   
17.52.1 ExoEZ Exosome Isolation Kit   
17.53  Evora Biosciences SAS   
17.54  Evox Therapeutics, Ltd.   
17.54.1 Protein Therapeutics  
17.54.2 RNA Therapeutics  
17.55  ExBiome BV   
17.55.1 ExomiR Technology   
17.56  Exrkine Corp.   
17.57  ExoCan Healthcare Technologies, Pvt. Ltd.   
17.57.1 ExoEnrich Exosome Isolation Kit   
17.57.2 ExoEngineering   
17.58  ExoCoBio, Co., Ltd.   
17.58.1 Products   
17.59  Exogenus Therapeutics   
17.60  ExoPERT   
17.60.1 EXo-i   
17.61  ExoPharm   
17.61.1 LEAP Technology   
17.61.2 Cevaris & Plexaris   
17.61.3 Partnering Strategy  Exosome Technologies  Exosome Medicines   
17.62  ExosomeDx (biotechne)   
17.62.1 ExoDX Prostate Test   
17.62.2 Pharma Services   
17.63  ExosomePlus   
17.64  Exosome Sciences   
17.64.1 TauSome Biomarker   
17.65  Exosomics S.p.A   
17.65.1 ExoRef   
17.65.2 SeleCTEV-DNA Enrichment Kits   
17.65.3 SoRTEV-RNA Enrichment Kits   
17.65.4 evGAG   
17.66  ExoVectory   
17.66.1 EVY-101   
17.67  Florica Therapeutics   
17.68  GenWay Biotech, Inc.   
17.69  HansaBioMed Lifesiences, Ltd.   
17.69.1 Products   
17.70  ILIAS Biologics, Inc.   
17.70.1 EXPLOR   
17.70.2 Exo-Target   
17.71  Innocan Pharma   
17.71.1 CBD-Loaded Exosomes   
17.72  Innovex Therapeutics, S.L   
17.72.1 Research & Development   
17.73  INOVIQ, Ltd.   
17.73.1 EXO-NET (Research Use only)   
17.74  Invent Biotechnologies, Inc.   
17.75  Izon Science, Ltd.   
17.75.1 qEV Isolation   
17.76  Kimera Labs, Inc.   
17.76.1 XoGlo   
17.76.2 XoGlo Pro   
17.76.3 Equisome HC   
17.77  Leading Biology, Inc.   
17.78  LifeSpan Biosciences, Inc.   
17.79  Lonza Group, Ltd.   
17.79.1 Exosome Service   
17.80  Mantra Bio   
17.80.1 Partnering   
17.81  MDimune, Inc.   
17.81.1 BioDrone Technology   
17.82  Miltenyi Biotech B.V. and Co., KG   
17.82.1 qEV Exosome Isolation Kit   
17.83  miR Scientific   
17.83.1 Prostate Cancer Test   
17.84  Mursla, Ltd.   
17.84.1 ExoPheno   
17.85  MyBioSource, Inc.   
17.86  NanoSomics, Inc.   
17.86.1 Technology   
17.87  NanoView Biosciences   
17.87.1 ExoView R200   
17.87.2 ExoView R100   
17.87.3 ExoView Tetraspanin Kits   
17.87.4 ExoFlex Kits   
17.88  NeurExo Sciences   
17.88.1 Research & Development Programs   
17.89  NeuroDex, Inc.   
17.90  NurExone Biologic Ltd   
17.91  New England Peptide, Inc.   
17.91.1 ME- Kit for Exosome Isolation   
17.92  Norgen Biotek Corp.   
17.92.1 Services   
17.93  Novus Biologicals, LLC   
17.93.1 Exosome Research Tools   
17.94  nRix Dx, Inc.   
17.95  Oasis Diagnostics Corporation   
17.95.1 Pure.SAL   
17.96  OmniSpirant, Ltd.   
17.96.1 Technology   
17.97  Organicell   
17.98  OriGene Technologies, Inc.   
17.99  Paracrine Therapeutics, Pvt. Ltd.   
17.100  QIAGEN   
17.100.1  ExoEasy Maxi Kit   
17.100.2  miRCURY Exosome Kits   
17.100.3  miRCURY LNA miRNA Focus PCR Panels   
17.101  ReNeuron   
17.101.1  Exosome Platform   
17.102  RION   
17.102.1  Technology   
17.103  RoosterBio, Inc.   
17.103.1  RoosterCollect-EV   
17.103.2  RoosterCollect EV Pro   
17.103.3  RoosterCollect-EV-CC   
17.103.4  EV Boost   
17.104  Rosetta Exosome   
17.106  System Biosciences, LLC   
17.106.1  Exosome Research Products   
17.106.2  Exosome Research Services   
17.107  Tavec Pharma   
17.107.1  Technology   
17.107.2  Acquisition by Therillia   
17.108  Theoria Science, Inc.   
17.108.1  Technology: ExoScreen   
17.109  Thermo Fisher Scientific   
17.109.1  Exosome Products for Testing and Research   
17.110  TransGen Biotech, Co., Ltd.   
17.111  TriArm Therapeutics, Co., Ltd.   
17.111.1  Exosome Engineering Platform   
17.112  United Therapeutics Corp.  
17.112.1  Unexisome  
17.113  Versatope Therapeutics  
17.113.1  VT-105  
17.114  Vesigen Therapeutics, Inc.  
17.114.1  Technology  
17.115  VivaZome Therapeutics, Pvt. Ltd.  
17.115.1  VivaZome’s Collaboration with ANU  
17.115.2  VivaZome’s Collaboration with ReNerve  
17.116  Xollent Biotech   
17.116.1  Pipeline  
17.117  XOStem, Inc.  
17.118  YMAIR Genomics, LLC  
17.118.1  Urine Biomarker Isolation Method  
17.118.2  Ymatrix 

FIGURE 2.1: Classification of Extracellular Vesicles   
FIGURE 2.2: Exosome Formation   
FIGURE 2.3: Exosome Uptake by Target Cells   
FIGURE 2.4: Structure of an Exosome   
FIGURE 2.5: Schematic of Membrane and Lumen Components of Exosomes   
FIGURE 2.6: Classification of Exosomes according to Origin   
FIGURE 2.7: Methods of Isolation for Natural Exosomes   
FIGURE 2.8: Exosomes with Loaded Therapeutics in the Lumen and Surface Display   
FIGURE 2.9: Schematic Representation of Therapeutic Applications of Exosomes   
FIGURE 2.10: Sources of Exosomes for Research   
FIGURE 3.1: Pre-Isolation Interior Modification Methods   
FIGURE 3.2: Post-Isolation Interior Modification Methods   
FIGURE 3.3: Surface Modification through the Parent Cells   
FIGURE 3.4: Direct Surface Modification   
FIGURE 5.1: Common Isolation Methods in Exosome Research   
FIGURE 5.2: Exosome Labeling Methods in Exosome Biodistribution Analysis   
FIGURE 5.3: Fluorescent Dyes used in Exosome Labeling   
FIGURE 5.4: Common Methods to Remove Unlabelled Probes   
FIGURE 5.5: Determination of Exosome Dose in Exosome Studies   
FIGURE 5.6: Routes of Exosome Administration   
FIGURE 5.7: Tested and Non-Tested Exosomes in Research   
FIGURE 7.1: Number of PubMed Publications on Exosomes   
FIGURE 7.2: Top Five Countries with Largest Number of Publications   
FIGURE 7.3: Number of PubMed Publications on Exosome DNA as Diagnostics   
FIGURE 7.4: Number of PubMed Publications on Exosome RNA as Diagnostics   
FIGURE 7.5: PubMed Publications on Exosome Proteins as Diagnostics   
FIGURE 7.6: PubMed Publications on Exosomes Derived from Stem Cells   
FIGURE 7.7: PubMed Publications on Exosome-based Diagnostics   
FIGURE 7.8: PubMed Publications on Exosome-based Therapeutics   
FIGURE 7.9: PubMed Publications on Exosomes for Cancer Diagnosis   
FIGURE 7.10: Publications on Exosome Diagnostics for Pregnancy Disorders   
FIGURE 8.1: Patents/Applications Related to Exosome-Sources   
FIGURE 8.2: Patents/Applications Related to Exosomes-Isolation/Preparation   
FIGURE 8.3: Patents/Applications Related to Type of Cargo   
FIGURE 8.4: Patents/Applications Related to Cargo Loading Methods   
FIGURE 8.5: Patents/Applications Related to Therapy Area   
FIGURE 8.6: Leading Assignees of Exosome Patents   
FIGURE 9.1: Exosome Clinical Trials by Geography   
FIGURE 10.1: Schematic Models of Continuous Exosome Manufacturing Approaches   
FIGURE 10.2: Upstream Cell Line Production Methods   
FIGURE 10.3: Downstream Exosome Purification Methods   
FIGURE 11.1: Diagrammatic Representation of Differential Centrifugation   
FIGURE 11.12: Diagrammatic Representation of Gradient Density Ultracentrifugation   
FIGURE 11.3: Diagrammatic Representation of Ultrafiltration & Sequential Ultrafiltration   
FIGURE 11.4: Diagrammatic Representation of Size-Exclusion Chromatography   
FIGURE 11.5: Diagrammatic Representation of Polymer Precipitation   
FIGURE 11.6: Diagrammatic Representation of Immunoaffinity Capture   
FIGURE 11.7: Diagrammatic Representation of Microfluidics-based Techniques   
FIGURE 11.8: Comparative Yield of Exosomes by Isolation Techniques   
FIGURE 11.9: Relative Viability of Exosomes by Isolation Technique   
FIGURE 12.1: Number of PubMed Published on Exosome Diagnostics   
FIGURE 13.1: Schematic Illustration of Key Points in Exosomes as Drug Delivery Systems   
FIGURE 13.2: Sketch of a Naïve Exosome with Not-Fully Identified Functional Molecules   
FIGURE 13.3: Passive Cargo Loading   
FIGURE 13.4: Active Cargo Loading with Anchored Cargo   
FIGURE 13.5: Active Cargo Loading with Free-Cargo   
FIGURE 15.1: Diagnostic Applications of Exosomes   
FIGURE 16.1: Market for Exosome Therapeutics and Diagnostics by Region, 2022-2030   
FIGURE 16.2: Market for Exosome Research Products by Region, 2022-2030   
FIGURE 16.3: Market Shares for Exosome Isolation Tools   
FIGURE 16.4: Percent Utilization of Research Tools used on Captured Exosomes   

TABLE 2.1: Molecular Contents of Exosomes   
TABLE 2.2: Common Protein Contents of Exosomes   
TABLE 2.3: Common Lipid Contents of Exosomes   
TABLE 2.4: Nucleic Acids Present in Cancer-Derived Exosomes   
TABLE 2.5: Types of Therapeutic Cargo used in Exosome Modifications   
TABLE 2.6: Differences between Exosome Therapy and Cell Therapy   
TABLE 2.7: Comparative Studies using Exosomes from Different Sources   
TABLE 3.1: Examples of Loaded and Displayed Molecules in Direct Exosome Engineering   
TABLE 3.2: Advantages and Disadvantages of Exosome Preparation Methods   
TABLE 3.3: Targeted Moieties used in Developing Targeted Designer Exosomes   
TABLE 3.4: Exosome-Based Clinical Trials for Cancer Treatment and Diagnostics   
TABLE 4.1: Select Preclinical Studies addressing Cardiovascular Diseases   
TABLE 4.2: Select Preclinical Studies addressing Kidney Diseases   
TABLE 4.3: Select Preclinical Studies addressing Liver Diseases   
TABLE 4.4: Select Preclinical Studies addressing Wound Healing   
TABLE 4.5: Select MSC Exosome-Based Clinical Trials for Regenerative Medicines   
TABLE 5.1: Comparison of MISEV2018 and MFDS2018 Guidelines   
TABLE 5.2: Comparison of Imaging Modalities used in Exosome Research   
TABLE 5.3: Comparison of Exosome Labeling Methods   
TABLE 6.1: Commercially Available Exosome Isolation Kits   
TABLE 6.2: Exosome-associated RNA Isolation Kits   
TABLE 6.3: Commercially Available Exosome Standards   
TABLE 6.4: Commercially Available Immunoplates for Capturing Exosomes   
TABLE 6.5: Commercially Available Immunobeads for Exosome Isolation   
TABLE 6.6: Commercially Available Exosome Marker Antibodies   
TABLE 8.1: Exosome Patent Assignees   
TABLE 9.1: Recruitment Status for Exosome-based Clinical Trials   
TABLE 9.2: Study Designs of Ongoing Exosome Clinical Trials   
TABLE 9.3: Study Phases in Clinical Trials   
TABLE 9.4: Phase III & Phase IV Studies in Clinical trials   
TABLE 9.5: Funding Types for Exosome-based Studies   
TABLE 9.6: Examples of Clinical Trials involving MSC-Derived Exosomes   
TABLE 9.7: Examples of Clinical Trials involving Drug-Loaded Exosomes   
TABLE 10.1: Companies Offering Exosome-Related Services   
TABLE 11.1: Current Strategies for Exosome Isolation   
TABLE 11.2: Active and Passive Methods of Microfluidics-based Platforms   
TABLE 11.3: Features of Microfluidics-based Techniques   
TABLE 11.4: Commercially Available Exosome Isolation Kits   
TABLE 11.5: Summary of Different Exosome Isolation Techniques   
TABLE 11.6: Approaches for Exosome Analysis of Gene and Protein Biomarkers   
TABLE 11.7: Emerging Optical Technologies for Exosome Analysis   
TABLE 11.8: Electrochemical and Electromechanical Approaches for Exosome Analysis   
TABLE 12.1: Exosomal Cargo as Biomarkers for Disease Diagnosis  
TABLE 12.2: Exosomal Proteins in Different Cancers   
TABLE 12.3: Types of RNA as Biomarkers for Cancers   
TABLE 12.4: Non-Coding RNAs in Exosomes as Biomarkers for Cancers   
TABLE 12.5: Exosome Biomarkers for Cancer from other Body Fluids   
TABLE 12.6: Target Exosome Molecules for Diagnosis in Pregnancy Disorders  
TABLE 12.7: Target Molecules of Exosomes for Diagnosis after Organ Transplantation   
TABLE 12.8: Examples of Clinical Trials involving Exosome-based Diagnostics   
TABLE 13.1: List of Commercial Companies Developing Exosomes Therapies   
TABLE 13.2: Summary of Cargo Loading Methods   
TABLE 13.3: Examples of Drugs Encapsulated in Exosomes   
TABLE 13.4: Preclinical Studies involving Drug-Loaded Exosomes   
TABLE 13.5: Phase III Clinical Trials involving Exosome Therapeutics   
TABLE 14.1: The Potential of a New Approach to Cancer Vaccines in Animal Models   
TABLE 14.2: Ongoing Clinical Trials of Exosome-Based Cancer Immunotherapy   
TABLE 15.1: Companies Developing Exosome-Based Diagnostics   
TABLE 15.2: Select Clinical Trials Evaluating Exosome Diagnostics   
TABLE 15.3: List of Commercial Companies Developing Exosome Therapeutics   
TABLE 15.4: Promising Exosome-Based Therapeutic Candidates   
TABLE 15.5: A Short List of Diseases Addressed by Exosome Therapeutics   
TABLE 15.6: Current Clinical Trials Update on Exosomal Vaccine Development   
TABLE 15.7: Select Exosome-Based Clinical Trials   
TABLE 15.8: The List of NIH Funding for Exosome-Based Research in 2022   
TABLE 15.9: Deals and Fund Raising in Exosome Space, 2016-2022   
TABLE 15.10: The Four Categories of Exosome Companies   
TABLE 15.11: Exosome Technologies Developed by Commercial Companies   
TABLE 16.1: Market for Exosome Therapeutics and Diagnostics by Region, 2022-2030   
TABLE 16.2: Market for Exosome Research Products by Region, 2022-2030   
TABLE 17.1: Aruna Bio’s Product Pipeline   
TABLE 17.2: BioCat’s Exosome Tools: An Overview   
TABLE 17.3: BreStem’s Pipeline   
TABLE 17.4: Capricor’s Product Pipeline   
TABLE 17.5: Cell Factory’s Exosome Drug Candidates   
TABLE 17.6: Codiak’s engEx Therapeutic Pipeline   
TABLE 17.7: Coya’s Pipeline   
TABLE 17.8: Curexsys’ Products in Pipeline   
TABLE 17.9: ILIAS Product Pipeline   
TABLE 17.10: MDimune’s Exosome-Based Products in Development   
TABLE 17.11: NeurExo’s Research & Development Programs   
TABLE 17.12: Organicell’s Product Pipeline   
TABLE 17.13: Organicell’s Pipeline - Compassionate Use IND   
TABLE 17.14: RION’s Pipeline of Products   
TABLE 17.15: Xollent’s Product Candidates  
TABLE 17.16: All Known Exosome Companies Worldwide by Region and Activity 

Companies Mentioned

  • 101 Bio
  • Abbexa, Ltd.
  • Abnova
  • Adipomics, Inc.
  • Aegle Therapeutics
  • Aethlon Medical, Inc.
  • AgeX Therapeutics
  • Ambiotech
  • AMS Biotechnology, Ltd. (AMSBIO)
  • Anjarium Biosciences
  • Antibodies-Online GmbH
  • Aposcience AG
  • Aruna Bio
  • ArunA Biomedical
  • Astellas
  • Avalon GloboCare Corp.
  • Aviva Systems Biology
  • Azymus Therapeutics
  • Beckman Coulter Life Sciences
  • Bio-Techne
  • BioCat GmbH
  • BioFluidica
  • Biological Dynamics, Inc.
  • Biorbyt, Ltd.
  • BioRegenerative Sciences, Inc.
  • BioVision, Inc.
  • Boehringer Ingelheim
  • BrainStorm Cell Therapeutics
  • BreStem Therapeutics, Inc.
  • Capricor Therapeutics
  • Carmine Therapeutics
  • CD Bioparticles
  • Cell Care Therapeutics
  • Cell Factory BVBA/Esperite NV
  • Cell Guidance Systems, Ltd.
  • Cellarcus Biosciences, Inc.
  • Ciola
  • CK-Exogene
  • Clara Biotech
  • Codiak Biosciences
  • Coya Therapeutics, Inc.
  • Craif, Inc.
  • Creative Bioarray
  • Creative Biolabs
  • Creative Medical Technology Holdings
  • Creative Proteomics
  • CreativeBiostructure
  • Curexsys GmbH
  • Diadem Biotherapeutics
  • Direct Bio
  • DLdevelop
  • Eli Lilly
  • Entelexo Biotherapeutics
  • EverZom
  • Evomic Science LLC
  • Evora Biosciences SAS
  • Evotec SE
  • Evox Therapeutics, Ltd.
  • ExBiome BV
  • Excella Bio
  • ExoCan Healthcare Technologies, Pvt. Ltd.
  • ExoCoBio, Co., Ltd.
  • Exocyte Therapeutics
  • Exogenus Therapeutics
  • ExoPERT
  • Exopharm Pty., Ltd.
  • Exosome Diagnostics, Inc (Bio-Techne)
  • Exosome Sciences
  • ExosomeDx (biotechne)
  • ExosomePlus
  • Exosomics S.p.A
  • ExoVectory
  • Exrkine Corp.
  • Florica Therapeutics
  • Fresenius Medical Care
  • GenWay Biotech, Inc.
  • HansaBioMed Lifesiences, Ltd.
  • ILIAS Biologics, Inc.
  • Innocan Pharma
  • Innovex Therapeutics, S.L
  • INOVIQ, Ltd.
  • Intezyne
  • Invent Biotechnologies, Inc.
  • Izon Science, Ltd.
  • Jazz Pharmaceuticals
  • Kimera Labs, Inc.
  • La Trobe University
  • Leading Biology, Inc.
  • LifeSpan Biosciences, Inc.
  • Lonza Group, Ltd.
  • Mantra Bio
  • MDimune, Inc.
  • Miltenyi Biotech B.V. and Co. KG
  • miR Scientific
  • Mursla, Ltd.
  • MyBioSource, Inc.
  • NanoSomics, Inc.
  • NanoSomiX
  • NanoView Biosciences
  • Navigo Proteins
  • NeurExo Sciences
  • NeuroDex, Inc.
  • New England Peptide, Inc.
  • Norgen Biotek Corp.
  • Novus Biologicals, LLC
  • nRix Dx, Inc.
  • NurExone Biologic Ltd
  • Oasis Diagnostics Corporation
  • OmniSpirant, Ltd.
  • Organicell
  • Orgenesis
  • OriGene Technologies, Inc.
  • Paracrine Therapeutics, Pvt. Ltd.
  • PureTech Health
  • Recipharms
  • ReNeuron
  • RION
  • Roche Pharmaceutical Company
  • RoosterBio, Inc.
  • Rosetta Exosome
  • Sarepta Therapeutics
  • System Biosciences, LLC
  • Takeda
  • Tavec Pharma
  • Theoria Science, Inc.
  • Thermo Fisher Scientific
  • TransGen Biotech, Co., Ltd.
  • TriArm Therapeutics, Co., Ltd.
  • UCI
  • Unicyte AG
  • United Therapeutics Corp.
  • Univercells Technologies
  • University of Adelaide
  • Versatope Therapeutics
  • Vesigen Therapeutics, Inc.
  • VivaZome Therapeutics, Pvt. Ltd.
  • Xollent Biotech
  • XOStem, Inc.
  • YMAIR Genomics, LLC


The content and statistics contained within the publisher's reports are compiled using a broad range of sources, as described below.

Input Sources

  • Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register, Chinese Clinical Trial Registry, Others)
  • Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
  • Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization, Google Patent Search)
  • Grant Funding Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK, Others)
  • Product Launch Announcements (Trade Journals, Google News)
  • Industry Events (Google News, Google Alerts, Press Releases)
  • Company News (SEC Filings, Investor Publications, Historical Performance)
  • Social Analytics (Google Adwords, Google Trends, Twitter, Topsy.com, Hashtagify.me, BuzzSumo.com)
  • Interviews with Stem Cell Industry Leaders

Research & Analysis Methodologies

The publisher employs the following techniques for deriving its market research:

  • Historical Databases: As the first and only market research firm to specialize in the stem cell industry, the publisher has 13+ years of historical data on each segment of the stem cell the industry. This provides an extremely rare and robust database for establishing market size determinations, as well as making future market predictions.
  • Prolific Interviews with Industry Leaders: As the global leader in stem cell industry data, the publisher has interviewed hundreds of leaders from across the stem cell industry, including the CEO of FUJIFILM CDI, FUJIFILM Irvine Scientific, Pluristem Therapies, Celularity, and many others.
  • Industry Relationships: The research team and its President/Founder, Cade Hildreth, Chair and present at a wide range of stem cell industry events, including Phacilitate's Advanced Therapies Week, World Stem Cell Summit (WSCS), Perinatal Stem Cell Society Congress, AABB's International Cord Blood Symposium (ICBS), and other events hosted within the U.S. and worldwide.
  • Global Integrated Feedback: Because the publisher maintains the world's largest stem cell industry news site that is read by nearly a million unique readers per year and the company has large social media audiences (25.7K+ followers on Linked, 21.2K+ followers on Twitter, and 4.3K+ followers on Facebook), the publisher is able to publish content relevant to the industry and receive immediate feedback/input from a global community of readers. In short, the publisher's data is crowd-sourced from market participants worldwide, including those in diverse geographic regions.
  • Preliminary Research: In addition to the interviews described above, the publisher conducts market surveys, executes social media polls, and aggregates market data from stem cell industry announcements, press releases, and corporate filings/presentations.
  • Secondary Research: The publisher summarizes, collects and synthesizes existing market research that is relevant to the market area of interest.
  • Future Projections: Using the resources described above, the publisher is uniquely positioned to make future projections about market size, market growth by segment, market trends, technology evolution, funding activities (financing rounds, M&A, and IPOs), and importantly, market leadership (market share by company).